🔗 Share this article

As the US continues making unprecedented adjustments to its vaccine schedules, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by questioning Covid vaccinations throughout the pandemic and has zeroed in on potential fatalities after Covid vaccination in her recent position at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Vaccine Schedule

Agency leaders planned to reveal major revisions to the childhood immunization program in December, bringing the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US at odds with many the global community with no evidence for public health gain. The announcement has been postponed until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the division this year.

A New Direction at the Agency

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood immunization guidelines in the US so as to align more like the Danish model, a society with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – usually the domain of Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Expertise

The appointee has no obvious track record in medication creation, oversight or management, which has been typical for previous leaders of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, stated Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a major agency. She is not an expert in drug approvals.”

Former directors of the center would “be deeply familiar with legal statutes and the research of medication creation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that prior appointees who led the center have had.”

CDER has an enormous portfolio at the FDA, she emphasized.

“Many people just focuses on the innovative therapies, but the generic program clears thousands of generic drugs. There’s a biosimilars division, OTC medication office and other areas, and each of these need to be managed,” she explained. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management component to the role, which oversees in excess of 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” the former official concluded.

Response and Disputed Programs

When asked about questions about Høeg’s qualifications and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a spokesperson responded that the “questions rely on flawed assumptions”.

“This background matches the functions of her job,” the representative explained, citing the period Dr. Høeg spent advising the agency head on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a contentious expedited therapy clearance system that allegedly worried her former heads. “How are these drugs being chosen for this expedited pathway? Who takes the choices?” Dr. Howard said. “There is a lot of lack of transparency happening at the agency right now.”

In general, he remarked, “the agency appears to be shifting towards more relaxed regulations of most medications, aside from immunizations.”

Established History on Vaccines

With vaccines, Dr. Høeg has a more established, if problematic, past, critics observe. She published a study using non-validated public submissions to assess the rate of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new government included revising guidelines for recently developed shots and discontinuing “unnecessary” vaccines, she said post-election on a podcast. At the agency, Dr. Høeg has reportedly suggested preventing young men from receiving Covid vaccinations.

“She is an complete ideologue who starts off with her beliefs and reverse-engineers to accommodate the science in a extremely disingenuous, fraudulent manner,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg aligned with other dissenters, {like|